different histologic variants have been described, namely, the hyaline vascular (HV) type, the plasma cell (PC) type, and the mixed cell (MC) type [2, 3] . The HV type, which corresponds to Castleman seminal description, is usually found in asymptomatic young adults, whereas the PC and MC types are usually associated with constitutional symptoms, anemia, hypergammaglobulinemia, and inflammatory syndrome. These symptoms may resolve after surgical removal.
The first cases of multicentric Castleman disease (MCD) were reported in the late 1970s and showed a dramatically worse prognosis, often with fatal outcome [4] . Multicentric cases were defined by the involvement of at least 2 noncontiguous lymph node areas. Pathological findings were usually consistent with the PC or MC type. With the emergence of the human immunodeficiency virus (HIV) pandemic, MCD appeared to be more frequent and closely linked to the presence of Kaposi sarcoma (KS) [5] [6] [7] [8] . In 1995, Soulier et al showed, in a series of 31 patients, that human herpesvirus 8 (HHV-8) DNA could be detected in 100% (14/14) of the CD biopsy specimen from HIV-positive patients and 41% (7/17) of the samples from HIV-negative patients [9] . Since then, almost all cases of CD observed in the setting of HIV infection were reported to be multicentric and associated with HHV-8.
Clinical presentation, evolution, and pathological and laboratory features of HIV-positive MCD have been extensively studied [10] [11] [12] [13] [14] [15] . In contrast, there is no published series of HHV-8-related CD in patients not infected with HIV. We report on a series of 18 HIV-seronegative patients with HHV-8-positive CD, and describe the clinical, pathological, and laboratory features of the disease.
METHODS

Patients
HIV-negative patients with pathologically proven CD were selected from the database of the Department of Clinical Immunology and the Department of Pathology at Hôpital Saint-Louis in Paris. During the study period ( January 1995 to June 2012), HHV-8 testing has been performed routinely for all CD cases, either at diagnosis or retrospectively. All CD cases screened for HHV-8 and occurring in HIV-negative patients were selected for the present study.
Case Selection
The diagnosis of CD was based on routinely hematoxylin and eosin-and Giemsa-stained sections. Criteria for CD diagnosis were normal lymph node architecture, "onion skin" mantle zone hyperplasia, and vascular hyperplasia. Germinal center depletion or hyalinization, and interfollicular plasmocytosis were complementary criteria, defining HV type, PC type, and MC type when the former, the latter, or both were prominent. Histologic review was conducted by one of the authors (V.M.).
HHV-8-positive cases were defined by a positive immunostaining against the HHV-8 latent nuclear antigen (LANA-1) on pathological sections. In cases without available histological material for immunostaining, a positive real-time polymerase chain reaction (rt-PCR) for HHV-8 on blood samples was required.
HHV-8 DNA detection (rt-PCR amplification assay) and detection of HHV-8 antibodies was performed on peripheral blood samples as previously described [16] .
RESULTS
Castleman disease was diagnosed in 59 HIV-negative patients. Four of them were excluded after histological review, as the final diagnoses were not consistent with CD. Of the 55 remaining cases with definite CD, 30 were multicentric and 25 localized. Eighteen cases, 16 identified by LANA-1 immunostaining and 2 more by rt-PCR, were associated with HHV-8 and were included in this study. All these cases were multicentric.
Patients
Main results are summarized in Table 1 . Eighteen patients (13 men, 5 women), aged 42-83 years (median, 65.9 years) were identified. Five originated from sub-Saharan Africa, 6 from northern Africa, 3 from southern Europe, 1 from the Antilles, and 3 from France. One of the 3 patients from France was a man who had sex with men. Five patients ( patients 1, 6, 15, 17, and 18) presented with type 2 diabetes mellitus; patient 3 reported chronic alcohol abuse; patient 14 had a concomitant diagnosis of benign thymoma; and patients 12, 16, and 18 presented with solid neoplasia (lung, breast, and laryngeal cancer, respectively) several years prior to CD diagnosis. All 3 had been treated by surgery and/or radiotherapy and were considered in remission at the time of CD diagnosis. None of the 18 patients received immunosuppressive drugs at the time of CD diagnosis. Patients 2 and 16 had been treated for tuberculosis. No other opportunistic infection was reported.
Clinical Features
All patients presented with constitutional symptoms, consisting of fever (n = 17), night sweats (n = 15), fatigue (n = 18), and weight loss (n = 17; median, 4 kg [range, 1-16 kg] ). These symptoms waxed and waned in 13 cases, with flares lasting for a few weeks before spontaneous resolution. The median time between disease onset and diagnosis was 6 months (range, 2-49 months). All patients presented asymmetrical peripheral lymphadenopathy involving cervical (n = 17), axillary (n = 17), or inguinal (n = 16) areas. Hepatomegaly and splenomegaly were present in 9 and 13 cases, respectively, with a huge spleen (>20 cm) in 5 cases. Computed tomographic scans revealed mediastinal (n = 13) and/or retroperitoneal (n = 16) lymphadenopathy in most cases. Lymphoid organs enlargement regressed in remission in most cases, at least partially. Eight patients presented with peripheral edema and 5 with pleuropericardial effusion or ascites. Two of them had primary effusion lymphoma (PEL).
Kaposi sarcoma lesions were observed in 9 cases (50%), and were present at diagnosis in 8. Patient 10 developed KS lesions 4 years after MCD diagnosis, soon after introduction of corticosteroid therapy for autoimmune thrombocytopenic purpura (AITP). Besides KS, 5 patients presented other skin manifestations such as cherry angioma, livedo, and telangiectasia. 
Monoclonal Gammopathy 
Laboratory Findings
Main results are summarized in /L). White blood cells abnormalities were noted during the flares on blood smear analysis in 13 of 16 patients (81%): atypical lymphocytes (n = 4), hyperbasophilic lymphocytes (n = 7), plasmocytosis (n = 7), or myelocytosis (n = 7). The platelet count was <50 × 10 9 /L in 5 cases (28%) and between 50 and 150 × 10 9 /L in 2 cases (11%). Serum fibrinogen concentration was >4 g/L in 13 of 18 cases (72%) and serum C-reactive protein level was high in all cases (median, 111 mg/L [range, 36-423 mg/L]). Serum albumin concentration was <30 g/L in 8 of 18 cases (44%). Hypergammaglobulinemia, (range, 15-55 g/L) was observed in 17 of 18 cases (94%) with a global increase in all immunoglobulin subtypes. Ten patients (55%) had monoclonal gammopathy at low concentrations.
PCR for HHV-8 DNA was positive at least once during follow-up on blood samples in all cases (18/18), and was significantly higher during the flares than in remission (median, 5.7 vs 2 log 10 copies of HHV-8 DNA per 10 6 cells, P = .0001,
Wilcoxon matched-pairs test; Figure 1 ). Twelve of 16 patients (75%) tested had a positive HHV-8 serology at diagnosis.
Pathological Findings
All 18 cases showed the classic histological features of CD of the mixed cell type or of the plasma cell type, including depleted germinal centers, expanded mantle zones, prominent infiltration of plasma cells in the interfollicular region, and vascular hyperplasia. Samples were available for LANA-1 immunostaining in 16 cases. HHV-8-infected cells were detected in all tested cases (16/16; Figure 2 ). Localized foci of Kaposi sarcoma were detected in the lymph node biopsy of 2 cases. Thirteen patients had a bone marrow examination by biopsy (n = 7) and/or aspiration (n = 9), showing in 10 cases a polytypic plasmocytosis ranging from 4% to 21%.
Associated Complications
Reactive Hemophagocytic Syndrome Reactive hemophagocytic syndrome (RHS), as defined by Janka et al [17] , was present at diagnosis or during relapses in 8 cases (44%). There was no association between the occurrence of RHS and HHV-8 viral load (Figure 3 ). Six patients required intensive care because of hemodynamic and/or neurological failure. All 8 cases were treated with intravenous etoposide. Two of them died with multiple organ failure. In the 6 other cases, symptoms improved dramatically within a few days after etoposide was started.
Autoimmunity
Fourteen of 16 tested patients (87.5%) presented with a positive direct antiglobulin test during flares. Six patients (33%) presented with AIHA. AIHA evolution was closely linked to that of MCD. AIHA was controlled with corticosteroids alone in 3 cases, concomitantly to MCD improvement in 2 cases, and after splenectomy in 1 case. Two patients with AIHA also presented with AITP. One of them developed PEL a few months after AITP onset. In both cases, AITP was persistent with moderate response to intravenous immunoglobulin therapy as well as to corticosteroids.
Patient 6 presented with thrombotic microangiopathy (TMA) associated with ADAMTS 13 autoantibody. TMA was difficult to control and its evolution paralleled that of MCD. After the introduction of etoposide, MCD symptoms resolved, blood HHV-8 viral load became undetectable, and ADAMTS 13 activity normalized.
Lymphoma
Two patients developed PEL, 5 years ( patient 10) and 9 years ( patient 16), respectively, after MCD diagnosis. Both of them died with multiple organ failure associated with lymphoma progression. Patient 9 presented with bilateral brachial plexus palsy. Cerebrospinal fluid analysis showed mild lymphocytosis, and magnetic resonance imaging of the brachial plexus indicated a tissular infiltration. Lymphoma was therefore suspected and this patient was successfully treated with an intensive immunochemotherapy regimen. Patient 12 presented at the same time HHV-8 related MCD and a lymphoplasmacytic lymphoma. Lymph node examination showed the classic histological features of HHV-8 CD and an interfollicular infiltration of monotypic immunoglobulin M lambda LANAnegative lymphoplasmocytes. This latter B-cell population was monoclonal, as evidenced by PCR amplification of the immunoglobulin heavy chain, and bone marrow examination confirmed lymphoma infiltration.
Kidney Involvement
Two patients presented with renal disease. Patient 6 experienced acute renal failure in the context of TMA. Patient 15, who also suffered from hypertension and diabetes mellitus, presented transient acute renal failure episodes with glomerular proteinuria during the MCD flares, which fully resolved with MCD control.
Lung Involvement
Patients 5 and 15 presented, during the flares, bilateral alveolar infiltrates that fully resolved after MCD control. Patient 3 developed bronchiolitis obliterans without paraneoplastic pemphigus, and desmoglein 1 and 3 antibody testing was negative. Respiratory symptoms as well as spirometric analysis partially resolved after MCD control.
Other Complications
Patient 7 presented with retroperitoneal fibrosis with bilateral ureteral obstruction. MCD-related symptoms as well as retroperitoneal fibrosis fully resolved after treatment with etoposide, and interferon-α was started. Comparison With HHV-8-Unrelated MCD Main results are summarized in Table 3 . Demographic characteristics were similar in the 18 patients with HHV-8-positive MCD and in the 12 patients with HHV-8-negative MCD except that most patients with HHV-8-positive MCD originated from a country with a high prevalence of HHV-8 infection. However, symptoms followed more frequently a relapsing and remitting course in HHV-8-positive MCD (72% vs 33%). Spleen enlargement and KS lesions were also more frequent in this group. Anemia was more severe in HHV-8-positive MCD and often related with AIHA or RHS. Lymphoma was more frequent in HHV-8-positive MCD. In contrast, arthritis, cutaneous manifestations, renal disease, lupus symptoms, or POEMS syndrome symptoms were more frequently observed in patients with HHV-8-negative MCD (Table 3) .
Treatment
Clinical remission was defined by the resolution of constitutional symptoms and of biological inflammatory markers.
Complete regression of lymphoid organ enlargement was not mandatory.
Ten patients (55%) have received corticosteroids. Corticosteroids showed little or no effect on lymphoid organ enlargement, inflammatory markers, or RHS. Occurrence or worsening of KS appeared in 1 patient each soon after corticosteroids introduction. Nevertheless, corticosteroids alone were effective in controlling AIHA in 3 of 6 patients.
Etoposide administered intravenously or orally induced clinical remission in most cases (13/15); vincristine and vinblastine were less effective with a response in 0 of 1 and 1 of 3 patients, respectively. However, etoposide showed only suspensive efficiency as all 7 patients treated with etoposide as a single-agent therapy experienced relapse within a few weeks after treatment was stopped. Etoposide reintroduction was usually effective. Two patients failed to respond to etoposide. One died with multiple organ failure (patient 4) and 1 only achieved remission after intensification of the chemotherapy regimen with rituximab and cyclophosphamide (patient 14). Other cytotoxic drugs used to treat KS, such as bleomycin (n = 4) or liposomal doxorubicin (n = 1), did not show any effect on MCD symptoms.
Thirteen patients were treated with rituximab. Among them, 10 received rituximab (375 mg/m 2 /week × 4 cycles) in addition to etoposide as previously used in HIV-infected patients [12] ; 3 patients received rituximab in association with combined chemotherapy: patient 9 because of suspected lymphoma, patient 12 because he was concomitantly diagnosed with lymphoplasmacytic lymphoma, and patient 14 because of progressive disease despite etoposide treatment. Three patients were lost to follow-up 2, 3, and 13 months, respectively, after rituximab treatment. With a median follow-up of 18 months (range, 1-99 months), only 2 patients have relapsed. Patient 15 and 13 have experienced 1 and several relapses, respectively, each time concomitantly to B-cell reconstitution. These relapses were successfully retreated with the association of rituximab etoposide. There was no case of lymphoma and 1 transient exacerbation of KS ( patient 14) after rituximab treatment during follow-up. Five patients did not receive rituximab. Among these patients, 2 developed fatal PEL. One more died from RHS soon after diagnosis.
DISCUSSION
HHV-8 infection is a cause of Kaposi sarcoma and of peculiar lymphoproliferative disorders such as PEL and MCD [9, 18, 19] . The relationship between HHV-8 and MCD has been extensively studied in the context of HIV infection, as almost all cases of MCD occurring in HIV-infected patients are related to HHV-8. Several lines of evidence support the etiologic role of HHV-8 in HIV-positive MCD pathogenesis. It can be demonstrated that HHV-8 infects large B cells with plasmacytic differentiation, mostly in the mantle zone but also in the interfollicular area [20] . HHV-8 is responsible for the in situ production of human interleukin 6 (IL-6) and its viral orthologue vIL-6, both cytokines being involved in B-cell proliferation and induction of inflammatory proteins synthesis, 2 pivotal markers of MCD [21] [22] [23] [24] . Moreover, infection of simian immunodeficiency virus-infected macaques with a simian analogue of HHV-8, the rhesus macaque rhadinovirus (RRV), is associated with the induction of a typical MCD [25] . In both contexts, human and simian, the occurrence of an HHV-8-or simian RRV-related lymphoproliferation requires either immune deficiency and/or coinfection with another virus. However, since the initial description of the association of HHV-8 and MCD, it has been shown that approximately 50% of the MCD cases occurring in a HIV-negative population were indeed also associated with HHV-8 [10] .
We report a large series of 18 patients with HIV-negative HHV-8 positive CD. Consistent with former reports [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , all of them had a multicentric presentation of CD, and there was no HHV-8-related localized CD in our series. Only 12 of 16 patients tested (75%) had a positive HHV-8 serology, pointing out the poor sensitivity of serology for the diagnosis of HHV-8 infection. In contrast, HHV-8 DNA could be detected in blood samples at least once during follow-up in all 18 cases.
All patients but 1 were aged >50 years, and none of them appeared otherwise immunocompromised. This finding echoes the recent observation by Powles et al that the incidence of HIV-associated MCD is increasing, particularly in older HIV-positive individuals with well-preserved immune function [13] . This could suggest an age-related specific immune deficiency leading to HHV-8 control loss.
Clinical and biological symptoms were very similar to those observed in HIV-infected patients with MCD, including the possible initial relapsing and remitting course [10, 15] . All patients presented with fever and other constitutional symptoms, lymphadenopathy, splenomegaly, biological inflammatory syndrome, hypoalbuminemia, polyclonal hypergammaglobulinemia, and frequently a positive direct antiglobulin test. Reactive hemophagocytic syndrome was a particularly frequent and life-threatening occurrence. The prevalence of KS lesions, 50% in our series, is comparable to that observed in the context of HIV infection [10, 15] . HHV-8 viral load was higher during the flares than in remission in all studied cases, which is similar to what is observed in HIV-positive MCD [11, 14] . In all cases, pathological findings were consistent with the plasmablastic type of MCD [20] . Etoposide therapy was highly effective in controlling disease flares, and rituximab led to sustained remission off chemotherapy. These responses to therapy are very similar to those observed in HIV-infected patients [12] . Finally, a high risk of developing non-Hodgkin lymphoma was observed in patients with HHV-8-related MCD, again resembling HIV-associated MCD [38, 39] , even though we did not observe any case of plasmablastic lymphoma in this small cohort largely treated with rituximab [39] .
In contrast, when comparing this series of 18 HIV-negative patients with HHV-8-associated MCD to a series of 12 HIVnegative patients with HHV-8-unrelated MCD, differences in demographics, clinical symptoms, and evolution could be observed between the 2 groups. Although age and sex ratio were similar between the 2 groups, most patients (15/18) with HHV-8-associated MCD originated from a country with a high prevalence of HHV-8 infection. Kaposi sarcoma was observed in 9 of the 18 patients and was not detected in the 12 patients with HHV-8-unrelated MCD. Patients with HHV-8-related MCD usually presented with more severe anemia often associated with autoimmune hemolysis and/or hemophagocytic syndrome, 2 complications that remained infrequent in patients with HHV-8-unrelated MCD. In contrast, patients with HHV-8-unrelated MCD presented a trend toward more frequent renal disease, arthritis, lupus-related symptoms, or POEMS syndrome symptoms. This latter finding is consistent with a previous study from Papo et al, who had found no association between HHV-8 infection and POEMS syndrome [40] .
In conclusion, in our study, HHV-8-associated CD in the absence of HIV infection was more similar to HHV-8-associated MCD in HIV-infected patients than to HHV-8-unrelated MCD in the absence of HIV infection. We propose that HHV-8-associated MCD might be considered a single clinicopathological entity, regardless of HIV status.
Notes
